D.A. Davidson & CO. Has $46.68 Million Stock Position in Pfizer Inc. (NYSE:PFE)

D.A. Davidson & CO. cut its stake in Pfizer Inc. (NYSE:PFE) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,759,441 shares of the biopharmaceutical company’s stock after selling 45,258 shares during the period. D.A. Davidson & CO.’s holdings in Pfizer were worth $46,678,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Citizens & Northern Corp grew its stake in Pfizer by 7.5% during the fourth quarter. Citizens & Northern Corp now owns 36,646 shares of the biopharmaceutical company’s stock worth $972,000 after buying an additional 2,545 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Pfizer by 0.3% in the 4th quarter. CIBC Asset Management Inc now owns 1,068,039 shares of the biopharmaceutical company’s stock worth $28,335,000 after acquiring an additional 2,701 shares in the last quarter. Pittenger & Anderson Inc. grew its position in Pfizer by 9,571.7% during the 4th quarter. Pittenger & Anderson Inc. now owns 102,520 shares of the biopharmaceutical company’s stock worth $2,720,000 after acquiring an additional 101,460 shares during the last quarter. Cutler Investment Counsel LLC acquired a new stake in Pfizer during the 4th quarter valued at $4,687,000. Finally, Human Investing LLC bought a new position in Pfizer in the 4th quarter valued at $85,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $25.50 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $144.48 billion, a P/E ratio of 18.08, a PEG ratio of 0.64 and a beta of 0.64. The business has a 50-day moving average of $26.28 and a 200-day moving average of $27.54. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.75%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Guggenheim reissued a “buy” rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Finally, UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.